FDA And FTC Join Forces On Biosimilars
Teaming Up To Eliminate Barriers To Biosimilar Competition
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
You may also be interested in...
AmerisourceBergen’s senior director of biosimilars, Sean McGowan, believes that momentum is continuing to build for US biosimilars in 2021, especially with key developments involving insulins and interchangeability on the horizon.
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
Sandoz CEO Richard Saynor says he sees promising signs from the US biosimilars market that suggest it is beginning to meet its potential, albeit remaining many years behind the European market.